STOCK MARKET BSE NSE

Centre, ICMR to Produce Files Relating to Cancer Drugs Licence

Published: 12th August 2014 02:48 PM  |   Last Updated: 12th August 2014 02:48 PM   |  A+A-

By PTI

NEW DELHI: The Supreme Court today directed the Centre's competent authority to place before it the file relating to licences given for the administration of two vaccines for cervical cancer prevention.      

The apex court also directed the Centre to place before it the report of Parliamentary Standing Committee on Health and Family Welfare which has dealt with the issue of drugs relating to HPV vaccine for prevention of cervical cancer.          

A bench comprising justices Dipak Misra and V Gopala Gowda also asked the Indian Council of Medical Research (ICMR) to place before it the file dealing with the vaccine and posted the matter for hearing on October 28.   

The two drugs in question are Gardasil and Cervarix, manufactured by Merck Sharpe and Dohme Pharmaceuticals and GlaxoSmithKline Limited, respectively.           

The bench said these files are required for examining various questions raised in the Public Interest Litigation (PIL).   

The bench also allowed to make Gujarat, Andhra Pradesh and Telangana as respondents in the matter because some villages in these states were chosen for administering the vaccine as an experiment and reports allegedly suggested that girls suffered side effects of these vaccines.       

The bench said it had to examine whether proper protocol and procedure was followed for the introduction of these vaccines because it has been alleged that deaths have also been caused due to the situation.            

The bench was hearing a PIL seeking to quash licensing of two vaccines for cervical cancer treatment on the ground that the approval for their use was done without adequate research on safety.  

It has been alleged that the Drugs Controller issued licences for the vaccines without adequate research on safety as directed by Parliamentary Standing Committee on Health and Family Welfare in 2010.

Petitioner Kalpana Mehta and other health activists had alleged that Gardasil and Cervarix are unproven and hazardous human papilloma virus (HPV) vaccines being marketed in India by MSD Pharmaceuticals Pvt Ltd and GlaxoSmithKline Ltd.     

The HPV vaccine prevents infection with certain species of human papillomavirus associated with the development of cervical cancer.  

The court passed the order on the petition pleading that licences be suspended and the vaccines be recalled as there has been no scientific basis to allow their administration.           

"The two companies have also flouted Indian law with impunity and have not done the post marketing studies ordered by the Drugs Controller at the time of licensing," the plea had alleged.

Stay up to date on all the latest Business news with The New Indian Express App. Download now

Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp